Recent Updates
Recently added Catalysts
ARGX

argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

Tuesday, April 11, 2017 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+42%
120-day peak, hindsight
Typical move
4%
average across 14 past catalysts
Lead asset
Empasiprubart
Phase 2 · Dermatomyositis

Full Press Release Details

argenx launches Phase II study of ARGX-110 as a monotherapy in relapsed/refractory CTCL patients.

Biotech snapshot

Lead asset
EmpasiprubartPhase 2
Dermatomyositis →

Catalyst track record

+42%
best trade around ARGX's most recent catalyst

Peak hindsight return over a 120-day window, across 14 tracked FDA/PDUFA catalysts for ARGX.

See every catalyst's timing & PoA →